Dr. Sanchorawala speaks on ASCT in AL amyloidosis
Vaishali Sanchorawala
The successful use of novel agents and data drawn from the ANDROMEDA trial (NCT03201965) is referenced as to why the utility of ASCT in AL amyloidosis may be questioned. However, Dr Sanchorawala does go on to explain how for a small patient population, ASCT is still a very useful tool. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
Clink link in video to watch.